Core Viewpoint - Huabei Pharmaceutical's subsidiary, Hebei Huamin Pharmaceutical Co., has received approval from the National Medical Products Administration for the marketing application of Cefotolan Pivoxil, a third-generation cephalosporin antibiotic [1] Group 1: Product Details - Cefotolan Pivoxil is a third-generation cephalosporin antibiotic that is hydrolyzed into the active form Cefotolan after absorption, exhibiting antibacterial properties [1] - The antibiotic shows significant effectiveness against five major pathogens causing community-acquired respiratory infections, particularly against penicillin-resistant Streptococcus pneumoniae and Staphylococcus aureus [1] Group 2: Indications - The product is indicated for infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and secondary infections from trauma, burns, and surgical wounds [1] - Additional indications include perianal abscess, pharyngitis, laryngitis, tonsillitis (including peritonsillar abscess), acute bronchitis, pneumonia, lung abscess, chronic respiratory infections, otitis media, sinusitis, periodontitis, jaw inflammation, cystitis, pyelonephritis, scarlet fever, and whooping cough [1]

Core Viewpoint - Company Huabei Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Cefotolan Pivoxil, a third-generation cephalosporin antibiotic [1] Group 1: Product Approval - Huabei Pharmaceutical's wholly-owned subsidiary, Hebei Huamin Pharmaceutical Co., Ltd., has been granted the marketing approval for Cefotolan Pivoxil [1] - Cefotolan Pivoxil is a third-generation cephalosporin antibiotic that is hydrolyzed into the active form Cefotolan after absorption [1] Group 2: Antibacterial Efficacy - Cefotolan Pivoxil shows significant effectiveness against five major pathogens causing community-acquired respiratory infections, particularly against penicillin-resistant Streptococcus pneumoniae and Staphylococcus aureus [1] - The drug is suitable for treating infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and various respiratory infections [1]

证券代码：600812 股票简称：华北制药 编号：临 2025-055 | 通用名称：头孢托仑匹酯 | | 化学原料药名称 | | --- | --- | --- | | 英文名/拉丁名：Cefditoren | Pivoxil | | | CYHS2460452 | | 受理号 | | 2025YS00962 | | 通知书编号 | | 境内生产化学原料药上市申请 | | 申请事项 | | YBY71282025 | | 化学原料药注册标准 编号 | | 个月 | 18 | 有效期 | | 25Kg/袋 | | 包装规格 | | 名称：华北制药河北华民药业有限责任公司 | 地址：石家庄经济技术开发区海南路 98 号 | 生产企业 | | Y20240000528 | | 登记号 | | 至 | 年 月 日 2030 11 2 | 通知书有效期 | | 根据《中华人民共和国药品管理法》及有关规定，经审查，本品 | 符合药品注册的有关要求，批准注册。 | 审批结论 | 二、药品其他相关情况 头孢托仑匹酯属于第三代头孢菌素抗生素，属于头孢托仑的特戊酰氧 甲酯，吸收后被水解为活性体头孢托仑而发挥抗菌作用，与其他第三 ...

Core Viewpoint - Company Huabei Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Cefotolan Pivoxil, a third-generation cephalosporin antibiotic [1] Group 1: Product Information - Cefotolan Pivoxil is a third-generation cephalosporin antibiotic that is hydrolyzed into its active form, Cefotolan, after absorption, providing antibacterial effects [1] - The antibiotic shows significant efficacy against five major pathogens causing community-acquired respiratory infections, particularly against penicillin-resistant Streptococcus pneumoniae and Staphylococcus aureus [1] - The product is indicated for various infections caused by sensitive bacteria, including superficial and deep skin infections, lymphangitis, chronic pyoderma, and respiratory tract infections [1]

Market Overview - The Shanghai Composite Index closed at 3976.52 points, above the annual line, with a gain of 0.55% [1] - The total trading volume of A-shares reached 21,329.04 million yuan [1] Stocks Breaking Annual Line - A total of 110 A-shares have surpassed the annual line today, with notable stocks including: - Deer Chemical with a deviation rate of 14.65% - Yabao Chemical at 11.35% - Fushi Holdings at 10.87% [1] Top Stocks by Deviation Rate - The following stocks had the highest deviation rates from the annual line: - Deer Chemical: 20.75% increase, latest price 16.06 yuan, deviation rate 14.65% [1] - Yabao Chemical: 11.98% increase, latest price 8.13 yuan, deviation rate 11.35% [1] - Fushi Holdings: 13.39% increase, latest price 5.76 yuan, deviation rate 10.87% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Meirui New Materials: 19.99% increase, latest price 18.97 yuan, deviation rate 9.48% [1] - Intercontinental Oil and Gas: 10.13% increase, latest price 2.61 yuan, deviation rate 9.37% [1] - Tianjin Pulin: 10.00% increase, latest price 22.23 yuan, deviation rate 7.84% [1]

Group 1 - The core viewpoint of the article highlights the successful issuance of a three-year technology innovation bond by North China Pharmaceutical Co., Ltd., led by the Shijiazhuang branch of Industrial Bank, with a total issuance scale of 500 million yuan [1] - This bond issuance marks the first technology innovation bond in the pharmaceutical industry of Hebei Province, setting a historical low for the interest rate of similar products in the region [1] - The funds raised will provide strong financial support for the company's key technological innovation areas, accelerating the transformation and implementation of innovative results [1] Group 2 - As of September 2025, the Shijiazhuang branch of Industrial Bank has provided over 20 billion yuan in financing support to enterprises in Hebei through investment banking services [2] - The branch has served 15 technology-based enterprises through various services, including non-financial bond underwriting, merger loans, and syndicate loans [2] - The bank plans to deepen its "commercial bank + investment bank" strategy, focusing on the full-cycle needs of technology innovation enterprises and leveraging specialized products like technology innovation bonds to inject stable financial momentum into these companies [2]

Core Viewpoint - The announcement details the successful issuance of the first phase of the 2025 technology innovation bonds by North China Pharmaceutical Co., Ltd. on October 22, 2025 [1] Group 1 - The company’s board of directors guarantees the announcement's content is free from false records, misleading statements, or significant omissions [1] - The issuance of the technology innovation bonds is part of the company's ongoing efforts to enhance its financial capabilities [1] - Relevant issuance documents can be found on the China Money website and the Shanghai Clearing House website [1]

Core Insights - Company reported a revenue of 2.21 billion yuan for Q3 2025, a year-on-year decrease of 5.12% [1] - Net profit attributable to shareholders was 35.01 million yuan, an increase of 14.85% year-on-year [1] - Basic earnings per share stood at 0.02 yuan [1] Financial Performance - For the first three quarters, the company achieved a revenue of 7.485 billion yuan, reflecting a year-on-year decline of 1% [1] - Net profit attributable to shareholders for the first three quarters was 159 million yuan, showing a significant year-on-year increase of 54.69% [1] - Basic earnings per share for the first three quarters was 0.092 yuan [1]

Core Viewpoint - North China Pharmaceutical (600812.SH) reported a decline in revenue for the third quarter, while net profit showed an increase year-on-year, indicating mixed financial performance [1] Financial Performance - The company achieved an operating revenue of 2.21 billion yuan in the third quarter, representing a year-on-year decrease of 5.12% [1] - The net profit attributable to shareholders was 35.006 million yuan, reflecting a year-on-year increase of 14.85% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 23.378 million yuan, which is a year-on-year decrease of 17.12% [1] - Basic earnings per share were reported at 0.020 yuan [1]

华北制药股份有限公司 第十一届董事会第二十三次会议决议公告 证券代码：600812 证券简称：华北制药 编号：临 2025-054 一、董事会会议召开情况 华北制药股份有限公司（以下简称"公司"）第十一届董事会第二十 三次会议于 2025 年 10 月 22 日向全体董事、监事及公司高级管理人员以电 子邮件形式发出会议通知，以通讯方式于 2025 年 10 月 24 日召开。本次会 议应出席董事 9 名，实际出席董事 9 名。会议的召集、召开和表决程序符 合《公司法》等法律、行政法规、部门规章、规范性文件和《公司章程》 的规定。 二、董事会会议审议情况 会议审议并以书面表决方式通过了以下议案： （一）审议通过《2025年第三季度报告》 具体内容详见公司同日刊登于《上海证券报》《中国证券报》和上海 证券交易所网站（www.sse.com.cn）的《2025 年第三季度报告》。 表决结果：同意 9 票； 反对 0 票； 弃权 0 票。 上述议案已经公司董事会审计委员会审议通过，并同意提交公司董事 会审议。 （二）审议通过《关于注销雄安分公司的议案》 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 ...